Macro biotech fund flows also affect the 23andMe stock price forecast, with renewed inflows marking possible momentum reversal. Powell last appeared on the program in April 2021 , about 11 months before the central bank began a two-year regimen of aggressive interest rate hikes to fight accelerating inflation rates. A big challenge for Regeneron these days is expanding its operations. First-quarter sales declined 4% year over year, falling to just over $3 billion. Its leading drug, Eylea -- an eye treatment, for wet age-related macular degeneration -- experienced a 26% drop, as competition has been increasing. Overall product sales were down by 20% this past quarter; strong collaboration revenue helped Regeneron avoid a bigger dip in its top line. The 23andMe stock price forecast remains sensitive to biotech regulatory shifts, with new genetic privacy laws potentially altering investor confidence.